Table 2.
Mixed model of the anti-S1 and -S2 antibody titers against SARS-CoV-2.
| Estimate (β) | Std. Error | 95% CI | p-Value | |
|---|---|---|---|---|
| Intercept | 0.27 | |||
| Age | 0.00 | 0.003 | −0.01, 0.00 | 0.15 |
| Sex | −0.05 | 0.065 | −0.18, 0.07 | 0.4 |
| SARS-CoV-2 infection before vaccination | 0.32 | 0.057 | 0.21, 0.43 | <0.001 |
| 21–28 days after second dose | 0.79 | 0.047 | 0.70, 0.88 | <0.001 |
| Three months after second dose | 0.10 | 0.047 | 0.00, 0.19 | 0.044 |
| 1–7 days after third dose | 0.27 | 0.047 | 0.18, 0.36 | <0.001 |
| 21–28 days after third dose | 1.0 | 0.047 | 0.91, 1.1 | <0.001 |
| Three months after third dose | 0.55 | 0.047 | 0.46, 0.64 | <0.001 |
| Prior to fourth dose | 0.35 | 0.047 | 0.25, 0.44 | <0.001 |
| 21–28 days after fourth dose | 1.2 | 0.047 | 1.1, 1.3 | <0.001 |
Mixed model in which the anti-S1 and -S2 antibody titers against SARS-CoV-2 represented the dependent variable. Antibody titers are analyzed as log10. Antibody titers 21–28 days after the first BNT162b2 dose were the reference group. A p-value < 0.05 was considered statistically significant.